Mesa Laboratories MLAB Biopharmaceutical Development — Goodwill Foreign Currency Translation Gain Loss

Other segment segments

Similar metrics at other companies

OPKPharmaceutical — Goodwill Foreign Currency Translation Gain Loss

-$1.76M—

ASHLife Sciences — Goodwill Foreign Currency Translation Gain Loss

-$5M—

BLCOPharmaceuticals — Goodwill, Foreign Currency Translation, Gain (Loss)

$13M+139%

FAInternational — Goodwill Foreign Currency Translation Gain Loss

-$1.24M-220%

ASHSpecialty Additives — Goodwill Foreign Currency Translation Gain Loss

-$1M—

CNKInternational Operating — Goodwill Foreign Currency Translation Gain Loss

$1.8M-47.1%

Questions, answered.

What is Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss?

Mesa Laboratories (MLAB) reported biopharmaceutical development — goodwill foreign currency translation gain loss of $725K in Q4 2025.

How has Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss changed year-over-year?

Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss increased by 71.0% year-over-year, from $424K to $725K.

What does biopharmaceutical development — goodwill foreign currency translation gain loss mean?

Reflects the impact of fluctuations in foreign exchange rates on the carrying value of goodwill denominated in currencies other than the reporting currency for the Biopharmaceutical Development segment. This metric highlights the sensitivity of the segment's intangible asset valuations to global macroeconomic volatility. It is a non-cash adjustment that impacts the balance sheet rather than operational cash flow.